The efficacy and safety of Salmeterol/Fluticasone Propionate 50/500ug BD vs Ipratropium/Albuterol 36/206ug QID in Chinese patients with moderate-to-severe COPD: A 12-week, multicentre, randomized, open-label, active-controlled, paralled-group study

Trial Profile

The efficacy and safety of Salmeterol/Fluticasone Propionate 50/500ug BD vs Ipratropium/Albuterol 36/206ug QID in Chinese patients with moderate-to-severe COPD: A 12-week, multicentre, randomized, open-label, active-controlled, paralled-group study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Salbutamol/ipratropium bromide (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Apr 2012 Official title amended as reported by Chinese Clinical Trial Register.
    • 29 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top